Editorial composite showing a pharmacy worker facing medicine shelves beside a close-up of hands signing a contract.

A study of GSK and Pfizer’s 2019 consumer-health combination in the Philippines estimates that the marginal cost of supplying Pfizer cough and cold medicines fell by 9.43%, yet the benefits were uneven. Pfizer’s prices declined, while prices rose for GSK and rival Sanofi. The findings show why lower corporate costs and lower prices are related, but not the same thing.

Read More

Latest Articles

Repeated choices can strengthen later preferences, study finds
Why the colleague who uses AI may gain an advantage at work
UK business activity strengthens in August despite continued services job cuts
Micron plans $10 billion research network for next-generation memory
YMTC parent seeks 33 billion yuan in Shanghai IPO after profit surge
Mitsubishi Electric agrees $1.4 billion deal for US power-market software group PCI
Why a strong ESG reputation can make a downgrade hurt more
Why companies keep paying for software nobody uses
AI needs more electricity. Why are data centres waiting years to connect to the grid?
Why effective leadership looks different across countries
Financial knowledge does not make people immune to scams
ScanSource agrees $220.5 million MicroAge deal to expand IT services